摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-3-氟苯甲酸甲酯 | 849758-12-9

中文名称
4-溴-3-氟苯甲酸甲酯
中文别名
——
英文名称
methyl 4-bromo-3-fluorobenzoate
英文别名
4-bromo-3-fluorobenzoic acid methyl ester
4-溴-3-氟苯甲酸甲酯化学式
CAS
849758-12-9
化学式
C8H6BrFO2
mdl
MFCD08436044
分子量
233.037
InChiKey
WDAFDKXHLVMFKA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    64-66
  • 沸点:
    270.1±25.0 °C(Predicted)
  • 密度:
    1.577±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    6.1
  • 危险品标志:
    Xi
  • 海关编码:
    2916399090
  • 危险性防范说明:
    P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    请保持冷态。

SDS

SDS:0ea3afdca57b299fc26f2f19ee2aa4d7
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 4-bromo-3-fluorobenzoate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 4-bromo-3-fluorobenzoate
CAS number: 849758-12-9

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H6BrFO2
Molecular weight: 233.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (Methyl 4-bromo-3-fluorobenzoate)

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-溴-3-氟苯甲酸甲酯是一种羧酸酯类生物,常作为制备多种药物的重要中间体。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-溴-3-氟苯甲酸甲酯2,2'-联吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 tris-(dibenzylideneacetone)dipalladium(0)18-冠醚-6硫酸 、 copper diacetate 、 sodium hexamethyldisilazane铁粉sodium carbonatepotassium carbonatecaesium carbonate 、 silver sulfate 、 溶剂黄146potassium nitrateN,N-二异丙基乙胺4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下, 以 四氢呋喃甲醇乙二醇二甲醚二氯甲烷N,N-二甲基乙酰胺1,2-二氯乙烷甲苯 为溶剂, 反应 57.49h, 生成
    参考文献:
    名称:
    [EN] QUINOLONE DERIVATIVES AS ANTIBACTERIALS
    [FR] DÉRIVÉS DE QUINOLONE COMME ANTIBACTÉRIENS
    摘要:
    这项发明属于药物化学领域,涉及抑制细菌旋转酶的化合物及其制药组合物,这些化合物可用作抑制细菌旋转酶活性和细菌感染的药物,并具有如下所述的Formula (I)的结构。该发明还提供了包含Formula (I)化合物的药物组合物,以及使用这些化合物和组合物治疗细菌感染的方法。
    公开号:
    WO2016020836A1
  • 作为产物:
    描述:
    甲醇4-溴-3-氟苯甲酸盐酸 作用下, 反应 3.0h, 以100%的产率得到4-溴-3-氟苯甲酸甲酯
    参考文献:
    名称:
    解决革兰氏阴性细菌中氟喹诺酮耐药性的拓扑异构酶抑制剂。
    摘要:
    自从五十年前发现喹诺酮类抗生素以来,作为广谱药物,已经取得了巨大成功,它通过双重抑制细菌DNA促旋酶和拓扑异构酶IV发挥其活性。在GyrA / ParC喹诺酮耐药性确定区域中,基于靶点的突变在很大程度上推动了耐药率的上升,侵蚀了其实用性,并威胁了这一至关重要的抗生素类药物的未来使用。本文中,我们描述了一系列4-(氨基甲基)喹啉-2(1 H)-one的发现和优化,以34为例,它们抑制细菌DNA促旋酶和拓扑异构酶IV并显示出对环丙沙星耐药的革兰氏阴性病原体的有效活性。X射线晶体学分析表明34 在拓扑异构酶IV-DNA裂解复合物中占据经典的喹诺酮结合位点,但是不与喹诺酮抗性确定区域中的残基形成显着接触。
    DOI:
    10.1021/acs.jmedchem.0c00347
点击查看最新优质反应信息

文献信息

  • [EN] SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY<br/>[FR] COMPOSÉS SULFONAMIDES AYANT UNE ACTIVITÉ D'ANTAGONISTE DE TRPM8
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2012124825A1
    公开(公告)日:2012-09-20
    Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.
    提供具有TRPM8拮抗活性的磺胺类化合物。公式(I)的磺胺类化合物或其药学上可接受的盐,或其前药:(I)其中环A是由(a)吡啶与苯环融合;或(b)吡啶与单环芳香杂环融合而成的双环芳香杂环,环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰基团结合,环B是(a)单环或双环芳香烃;(b)单环或双环脂环烃;(c)单环或双环芳香杂环;或(d)单环或双环非芳香杂环,环C是(a)苯环;或(b)单环芳香杂环,其他符号与规范中定义的相同。
  • PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
    申请人:Hadida Ruah Sara Sabina
    公开号:US20120196869A1
    公开(公告)日:2012-08-02
    The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    这项发明涉及对离子通道具有抑制作用的吡咯嘧啶-螺环哌啶酰胺化合物。该发明还提供了包括该发明化合物的药学上可接受的组合物,以及使用这些组合物治疗各种疾病的方法。
  • AROMATIC COMPOUND
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP1956009A1
    公开(公告)日:2008-08-13
    An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.
    以下公式表示的芳香族化合物或其药用可接受盐: 其中,环A是杂环,环B是碳环、杂环等,G1、G2、G3、G4和G5是CH或N,X是-NH-、-O-、-CH2-等,Y是- -、-CO-、-SO2-等,Z是单键、-CO-、-SO2-、-NH-、-O-、-S-、-CONH-、-SO2NH-等,R2是氢、烷基、烷氧基、卤素等,R3是碳环组、杂环组、烷基等, 作为控制CCR4功能的调节剂,对治疗或治疗支气管哮喘、特应性皮炎等疾病很有用。
  • BENZOTHIOPHENE DERIVATIVE
    申请人:DAIICHI SANKYO COMPANY, LIMITED
    公开号:US20160024060A1
    公开(公告)日:2016-01-28
    [Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
    [待解决问题] 旨在提供一种具有PDE10A抑制活性的化合物,并具有新颖结构,或其同位素或药用可接受盐,以及一种以该化合物作为活性成分的药物组合物。 [解决方案] 本发明提供了一种由通用公式(I)表示的化合物或其药用可接受盐。
  • AZAINDOLE GLUCOKINASE ACTIVATORS
    申请人:Berthel Steven Joseph
    公开号:US20110144105A1
    公开(公告)日:2011-06-16
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    提供的化合物为公式(I): 以及其中可接受的药用盐,其中取代基如说明书所述。这些化合物以及包含它们的药物组合物,可用于治疗代谢性疾病和障碍,例如,2型糖尿病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫